Yale University

Yale University comprises three major academic components: Yale College (the undergraduate program), the Graduate School of Arts and Sciences, and the professional schools. In addition, Yale encompasses a wide array of centers and programs, libraries, museums, and administrative support offices. Approximately 11,250 students attend Yale.

Featured Startups and Technologies

Kolltan Pharmaceuticals

a private company founded in 2007 to develop novel monoclonal antibody (mAb) and small-molecule drugs targeting receptor tyrosine kinases (RTKs). Kolltan’s primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine. Dr. Schlessinger’s laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation at atomic resolution for the oncogenic activity of mutations that have been identified in a variety of human cancers.

Achillion Pharmaceuticals

Achillion is an innovative biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s highly skilled and experienced discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease – HCV and resistant bacterial infections.

Alexion Pharmaceuticals

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.

Rib-X Pharmaceuticals

Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company’s Nobel Prize winning platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development.

Oasys Water

Oasys (Osmotic Application Systems) is a privately held Boston, MA based company developing a suite of proprietary energy and resource recovery products to address the growing, global water crisis. Engineered Osmosis is a platform for reducing cost in the production of clean water, power and energy through more efficient and sustainable utilization of resources.


Antibiotics have long been recognized as reliable drugs that have largely overcome the lethal and devastating causes of bacterial infections. All known classes of antibiotics are increasingly encountering widespread resistance by many prevalent bacterial pathogens that will continue to significantly affect human health in the coming decades. BioRelix is a drug discovery and development company focused on identifying new anti-infective drug treatments that will address these critical challenges in infectious disease treatment. Our competitive advantage resides in the use of novel patented bacterial RNA targets called RiboSwitches that were identified in the laboratory of BioRelix founder, Dr. Ronald Breaker. RiboSwitches are short stretches of messenger RNAs that bind small molecule metabolites and control genes that are essential for the survival of many disease-causing microbes. Several different classes of RiboSwitch RNAs have been identified and each potentially could serve as a novel anti-infective drug target. BioRelix owns a worldwide license to develop and market RiboSwitch targeted medicines and is building a portfolio of products.

Stavudine (Zerit®)

Stavudine is used in combination with other antiviral medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Stavudine is in a class of antiviral medications called nucleoside analogue reverse transcriptase inhibitors (NRTIs). It works by slowing the spread of HIV in the body.


We believe that we can achieve this by insisting on excellence in everything that we do – in working efficiently, in making data-driven decisions quickly, in advancing promising compounds rapidly and in leveraging our pipeline to establish partnerships and licensing agreements with leading biotechnology and pharmaceutical companies. The outcome of that strategy to-date is a diverse pipeline of 14 compounds at various stages of development. Our compounds target multiple receptor tyrosine kinases simultaneously, as well as key components of downstream signaling pathways that play important roles in cancer, inflammation and metabolic diseases. With world-class discovery capabilities, we have an engine to drive continued enhancement of our clinical pipeline, generating a flow of ongoing opportunities for creating value in the clinic and ultimately the commercial marketplace. We take a pragmatic approach to product development, internally developing programs with clear and relatively short paths to market and working with partners to develop those programs with more costly or complex development trajectories. Our current focus is on undertaking a vigorous and expansive clinical development program for our lead compound XL184, while making strategic investments in earlier pipeline programs with an eye toward reaching go/no-go decisions as efficiently as possible. As these earlier programs progress, we intend to maintain our strategy of balancing internal and collaborative development programs with out-licensing transactions. Aware that many of today’s patients with cancer and other serious diseases have significant unmet medical needs, we are driven by a sense of urgency in pursuing a better way to better medicine.

Contact Us

Office of Cooperative Research
443 Temple Street
New Haven, CT 06511

Phone: (203) 436-8096

E-mail: ocr@yale.edu